Exact Sciences Corporation

Exact Sciences Corporation reported robust revenue growth for the fiscal year ended December 31, 2025, generating $3.25 billion in total revenue. Despite this top-line expansion, the company recorded a net loss of $207.9 million, an improvement in operational efficiency reflected in a gross profit of $2.26 billion. The gross margin stood at approximately 69.5%, driven by a cost of sales of $984.2 million. Operating expenses remained substantial at $2.47 billion, primarily allocated to sales and marketing ($1.05B) and research and development ($523.0M), contributing to a loss from operations of $206.3 million. On the balance sheet, the company maintains a strong liquidity position with $956.0 million in cash and cash equivalents and total assets of $5.86 billion. Cash flow from operations was positive at $491.4 million, demonstrating the company's ability to generate cash despite net losses. The company continued to manage its capital structure, ending the year with total stockholders’ equity of $2.40 billion.

Key Takeaways